Regulatory Materials and Documents. Astellas shall assign to Ambit in the Transition Agreement all right, title and interest in and to all Regulatory Materials and Regulatory Approvals in the Terminated Country(ies) solely relating to Reversion Products, which Regulatory Materials and Regulatory Approvals are owned by Astellas or its Affiliates (collectively, “Supporting Documents”), provided that all Supporting Documents will be supplied by Astellas on an “as-is” basis only and Astellas shall have no liability whatsoever with respect to such Supporting Documents. Unless terminated by Ambit pursuant to Section 9.3.3, in which case Astellas shall bear all such costs each Party shall bear one-half (1/2) of the out of pocket costs relating to such transfer of Supporting Documents. The Transition Agreement shall contain CONFIDENTIAL terms governing the coordination of the Parties’ respective regulatory responsibilities with respect to Licensed Compounds and Products.
Appears in 4 contracts
Samples: Exclusive License and Collaborative Research, Co Development and Commercialization Agreement (Ambit Biosciences Corp), Exclusive License and Collaborative Research, Co Development and Commercialization Agreement (Ambit Biosciences Corp), Exclusive License and Collaborative Research, Co Development and Commercialization Agreement (Ambit Biosciences Corp)